As per attachment

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 19th August, 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sir, Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject, we would like to inform you that the Company has received a Intimation u/s 143(1) with the refund of tax of Rs 4.99 Crores for the AY 2025-2026. The relevant details to be disclosed are as under: Sr Particulars Details 1 Name of the authority GSK received the Intimation u/s 143(1) for AY 2025-2026 with the Refund of Rs 4,99,11,100/- on dated 19th Aug, 2026. 2 Nature and details of the action(s) taken, initiated or The said Refund is received post the Intimation order(s) passed u/s 143(1) of the Income Tax Act for the GSK assessment for the AY: 2025-2026. 3 Date of receipt of direction or order, including any Date of receipt of Refund in the Bank account ad-interim or interim orders, or any other on 18th Aug, 2026. communication from the authority 4 Details of violation(s) / contravention(s) committed or N.A. alleged to be committed 5 Impact on financial, operation, or other activities of Tax Refund received will be accounted in the the listed entity, quantifiable in monetary terms to the Tax Paid Assets account in Balance Sheet. extent possible Kindly take the same on the record. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151